Radiosurgery of parasellar meningiomas
|
|
- Sheena Shelton
- 6 years ago
- Views:
Transcription
1 Gamma Knife radiosurgery for sellar and parasellar meningiomas: a multicenter study Clinical article J Neurosurg 120: , 2014 AANS, 2014 Jason P. Sheehan, M.D., Ph.D., 1 Robert M. Starke, M.D., M.Sc., 1 Hideyuki Kano, M.D., Ph.D., 2 Anthony M. Kaufmann, M.D., 3 David Mathieu, M.D., 4 Fred A. Zeiler, M.D., 3 Michael West, M.D., Ph.D., 3 Samuel T. Chao, M.D., 5 Gandhi Varma, M.D., 5 Veronica L. S. Chiang, M.D., 6 James B. Yu, M.D., 6 Heyoung L. McBride, M.D., M.S., 7 Peter Nakaji, M.D., 7 Emad Youssef, M.D., 7 Norissa Honea, Ph.D., 7 Stephen Rush, M.D., 10 Douglas Kondziolka, M.D., 10 John Y. K. Lee, M.D., 8 Robert L. Bailey, M.D., 8 Sandeep Kunwar, M.D., 9 Paula Petti, Ph.D., 9 and L. Dade Lunsford, M.D. 2 1 University of Virginia, Charlottesville, Virginia; 2 University of Pittsburgh, Pennsylvania; 3 University of Manitoba, Winnipeg, MB; 4 University of Sherbrooke, QC, Canada; 5 Cleveland Clinic, Cleveland, Ohio; 6 Yale University, New Haven, Connecticut; 7 Barrow Neurological Institute, Phoenix, Arizona; 8 University of Pennsylvania, Philadelphia, Pennsylvania; 9 Taylor McAdam Bell Neuroscience Institute, Washington Hospital Healthcare System, Fremont, California; and 10 New York University, New York, New York Object. Parasellar and sellar meningiomas are challenging tumors owing in part to their proximity to important neurovascular and endocrine structures. Complete resection can be associated with significant morbidity, and incomplete resections are common. In this study, the authors evaluated the outcomes of parasellar and sellar meningiomas managed with Gamma Knife radiosurgery (GKRS) both as an adjunct to microsurgical removal or conventional radiation therapy and as a primary treatment modality. Methods. A multicenter study of patients with benign sellar and parasellar meningiomas was conducted through the North American Gamma Knife Consortium. For the period spanning 1988 to 2011 at 10 centers, the authors identified all patients with sellar and/or parasellar meningiomas treated with GKRS. Patients were also required to have a minimum of 6 months of imaging and clinical follow-up after GKRS. Factors predictive of new neurological deficits following GKRS were assessed via univariate and multivariate analyses. Kaplan-Meier analysis and Cox multivariate regression analysis were used to assess factors predictive of tumor progression. Results. The authors identified 763 patients with sellar and/or parasellar meningiomas treated with GKRS. Patients were assessed clinically and with neuroimaging at routine intervals following GKRS. There were 567 females (74.3%) and 196 males (25.7%) with a median age of 56 years (range 8 90 years). Three hundred fifty-five patients (50.7%) had undergone at least one resection before GKRS, and 3.8% had undergone prior radiation therapy. The median follow-up after GKRS was 66.7 months (range months). At the last follow-up, tumor volumes remained stable or decreased in 90.2% of patients. Actuarial progression-free survival rates at 3, 5, 8, and 10 years were 98%, 95%, 88%, and 82%, respectively. More than one prior surgery, prior radiation therapy, or a tumor margin dose < 13 Gy significantly increased the likelihood of tumor progression after GKRS. At the last clinical follow-up, 86.2% of patients demonstrated no change or improvement in their neurological condition, whereas 13.8% of patients experienced symptom progression. New or worsening cranial nerve deficits were seen in 9.6% of patients, with cranial nerve (CN) V being the most adversely affected nerve. Functional improvements in CNs, especially in CNs V and VI, were observed in 34% of patients with preexisting deficits. New or worsened endocrinopathies were demonstrated in 1.6% of patients; hypothyroidism was the most frequent deficiency. Unfavorable outcome with tumor growth and accompanying neurological decline was statistically more likely in patients with larger tumor volumes (p = 0.022) and more than 1 prior surgery (p = 0.021). Conclusions. Gamma Knife radiosurgery provides a high rate of tumor control for patients with parasellar or sellar meningiomas, and tumor control is accompanied by neurological preservation or improvement in most patients. ( Key Words radiosurgery Gamma Knife meningioma sellae parasellar oncology stereotactic radiosurgery Abbreviations used in this paper: CN = cranial nerve; GKRS = Gamma Knife radiosurgery; SRS = stereotactic radiosurgery. Parasellar and sellar meningiomas are clinically challenging for neurosurgeons to manage. The difficulty posed by these tumors relates to the potential morbidity associated with tumor exposure and dissection, their frequently firm consistency and vascularity, and their proximity to critical neuroendocrine, vascular, and cranial nerve (CN) structures. Such features usually hinder complete resection, whether by endoscopic or trans cranial skull base approaches. 5,10,41 Open surgical ap J Neurosurg / Volume 120 / June 2014
2 Radiosurgery of parasellar meningiomas proaches have been accompanied by widely varying rates of complete resection and procedure-related morbidity and mortality. 2,6,21,28,40,46,50,58 Initial resection has also been associated with significant risks of delayed recurrence. 21,23,35,43,47,50,53 With earlier detection of sellar and parasellar meningiomas using MRI and/or CT, these tumors are now diagnosed when they have a small to moderate volume. Such tumors often produce minimal symptoms. Stereotactic radiosurgery has been advocated for recurrent sellar and parasellar meningiomas after resection or as an upfront treatment for others. 17,51,52 To better define the outcomes of patients who have undergone stereotactic radiosurgery (SRS) as primary or adjuvant management, we performed a retrospective multiinstitutional analysis of patients who had undergone Gamma Knife radiosurgery (GKRS) for a sellar or parasellar meningioma. Methods Study Design and Patient Population Ten medical centers participating in the North American Gamma Knife Consortium (NAGKC) received individual institutional review board approval to submit their retrospective clinical outcome analysis of patients with sellar and parasellar meningiomas. An Excel spreadsheet database with selected variables was created and sent to all participating centers. The records of patients with meningioma who had undergone GKRS between 1988 and 2011 were assessed by each center for inclusion. Participating centers reviewed the medical records of their patients, entered data in the spreadsheet, and removed all patient identifiers from the data. Under institutional review board approval, an independent third party screened the pooled and de-identified data for errors. Ambiguities were addressed to the respective contributing center. Afterward, data were transmitted to the first author, who along with his coauthors devised this report. Patients were included in the study if they had a histologically diagnosed WHO Grade I meningioma involving the sellar and/or parasellar region. Patients were also included if they had clinical and imaging features consistent with a benign meningioma in this same neuroanatomical region. Such features would include a medical history absent of prior cancer and an intracranial tumor located in the sellar or parasellar region with MRI and/or CT features consistent with a meningioma. Such features included an extraaxial location, contrast enhancement, dural attachment, and, in some patients, tumor calcification. In addition, patients were required to have a minimum of 6 months of imaging and clinical follow-up after GKRS. Radiosurgical Technique The Models U, B, C, 4C, or Perfexion Gamma Knife units were used depending on the technology available to the various participating centers at the time of treatment. The radiosurgical procedure began with the application of the Leksell Model G stereotactic frame (Elekta Inc.) after applying a local anesthetic supplemented by additional sedation as needed. After the frame was placed, J Neurosurg / Volume 120 / June 2014 high-resolution stereotactic MRI was performed. In rare cases in which MRI was not feasible or when MRI distortion was a concern, stereotactic CT was performed. Thinsliced axial and/or coronal plane images were obtained after the administration of intravenous contrast. A neurosurgeon, radiation oncologist, and medical physicist then performed SRS dose planning. At each center, dose selection was based on an empirical algorithm that evaluated tumor volume, proximity to critical structures such as the optic apparatus and pituitary gland, preexisting neurological deficits, and history of treatment with fractionated radiation therapy. Clinical and Imaging Follow-Up Clinical and imaging evaluations were typically performed at follow-up intervals of 6 months for the first 2 years after radiosurgery. In patients demonstrating no evidence of either tumor growth or new neurological findings, follow-up intervals were increased to every 1 2 years. Whenever possible, patients underwent follow-up neurological examination and neuroimaging at the respective treating center. Endocrine testing was performed at the discretion of the treating physician and/or the patient s referring physician. Endocrine testing of patients included tests for cortisol, thyroid, gonadotropic, and growth hormone function. Since most of the participating institutions are referral centers for a broad geographic area, some patients underwent follow-up evaluations by their local physicians. For such patients, clinical notes and neuroimaging studies were received and reviewed by the clinicians who had performed the GKRS. Follow-up images were compared with the images obtained at the time of GKRS. Tumor dimensions were measured in the axial, sagittal, and coronal planes. Tumor volume was estimated by multiplying the left-right (x), anterior-posterior (y), and superior-inferior (z) dimensions and dividing this number by 2. Tumor growth within the planned treatment volume or adjacent to it was considered tumor progression. Statistical Analysis Calculations for a given parameter are based on the total number of patients with complete data for that parameter. Data are presented as the median or mean and range for continuous variables, and as the frequency and percentage for categorical variables. Statistical analyses of categorical variables were performed using the chisquare and Fisher exact test, as appropriate. Statistics of means were performed using the unpaired Student t-test both with and without equal variance (Levene s test), as necessary, and the Wilcoxon rank-sum tests when variables were not normally distributed. Kaplan-Meier plots for tumor progression free survival using the dates of the first SRS, follow-up MRI studies, and death or last follow-up. Progression-free survival and overall survival time were calculated from the day of the first SRS by using the Kaplan-Meier method. Univariate analysis was performed on the Kaplan-Meier curves using log-rank statistics. Factors predictive of tumor progression (p < 0.15) were entered into a Cox regression analysis to assess hazard ratios. 1 Patients with an unfavorable outcome were 1269
3 J. P. Sheehan et al. defined as those with worsening or new deficits following SRS or with tumor progression. Clinical covariates predicting an unfavorable outcome with a univariate p < 0.15 were included in multivariate logistic regression analysis. Clinically significant variables and interaction expansion covariates were further assessed in both Cox and logistic multivariate analysis as deemed relevant. A p 0.05 was considered statistically significant. Commercially available statistical processing software (Stata, version 11.0, Stata Corp.) was used. Results Patient Attributes The authors identified 763 patients with sellar and/or parasellar meningiomas treated with GKRS. The following centers contributed data: the University of Pittsburgh (281 patients), Yale University (11 patients), Cleveland Clinic (29 patients), University of Manitoba (27 patients), University of Sherbrooke (69 patients), Barrow Neurological Institute (158 patients), University of Pennsylvania (29 patients), Washington Hospital Center (2 patients), New York University (19 patients), and the University of Virginia (138 patients). The median patient age was 56 years (range 8 90 years). There was a clear sex predilection with 567 females (74.3%) and 196 males (25.7%). Three hundred fifty-five patients (50.7%) had undergone resection of a histologically confirmed WHO Grade I meningioma before GKRS; 55 patients (10.6%) had undergone more than one resection. The remaining patients displayed neuroimaging and clinical features consistent with a benign meningioma. Fractionated radiation therapy had been performed before GKRS in 3.9% of patients. Preoperative patient characteristics and presentations are detailed in Table 1. Tumor Attributes and Response One hundred fifty-six patients (32.4%) underwent treatment before 2000, whereas 325 patients (67.6%) received treatment after 2000; treatment dates were unknown in the remaining 282 patients. The mean tumor volume was 8.8 cm 3 (range cm 3 ). The median prescription dose delivered to the tumor margin was 13 Gy (range 5 30 Gy). The maximum dose varied from 10 to 60 Gy (median 28 Gy; Table 2). Many centers limited the maximum dose to the optic nerve and chiasm to between 8 and 12 Gy. The median follow-up after SRS was 66.7 months (range months). At the last follow-up, 74 (9.8%) of 758 patients with available imaging demonstrated tumor progression, 334 (44.1%) had a decrease in tumor volume, and 350 (46.2%) had unchanged tumor volumes (Table 3), which makes for a 90.2% overall tumor control rate. Actuarial tumor progression free survival rates at 3, 5, 8, and 10 years following SRS were 98%, 95%, 88%, and 82%, respectively (Fig. 1). Further surgery as planned treatment, shunting for hydrocephalus, or treatment due to tumor progression was performed in 23 (3.3%) of 690 patients. Additionally, 22 (3.2%) of 687 patients subsequently underwent fractionated radiation therapy because of tumor progression. TABLE 1: Attributes of patients with a sellar and/or parasellar meningioma before GKRS* Variable No. (%) total patients 763 females 567 (74.3) age in yrs mean 55.8 median 56 range 8 90 patients w/ resection pre-gkrs 355 (50.7) of 700 patients w/ >1 resection pre-gkrs 74 (10.6) of 700 patients w/ radiation therapy pre-gkrs 23 (3.8) of 598 patients w/ symptom other than headache 584 (78.7) of 742 patients w/ CN deficits prior to GKRS per no. CN deficits (23.5) of (40.7) of 688 >1 246 (35.8) of 688 patients w/ specific CN deficit prior to GKRS II 99 (14.5) of 684 III 167 (24.4) of 684 IV 56 (8.2) of 684 V 245 (35.8) of 684 VI 225 (32.9) of 684 time from diagnosis to GKRS in yrs mean 2.1 median 1 range 0 30 * Total number reflects the number of patients for whom evaluable data were available. There was no difference in the tumor progression free survival between patients with no prior resection (upfront radiosurgery) and those who had one prior surgical procedure (p = 0.996; Fig. 2). Patients who underwent more than 1 prior surgery were significantly more likely to have tumor progression despite radiosurgery (p = 0.004). Patients who underwent prior fractionated radiation therapy were 7.7 times more likely to have tumor progression (p < 0.001; Fig. 3). The pre-srs factors predictive of tumor progression in univariate analysis are shown in Table 4. TABLE 2: Gamma Knife radiosurgery parameters, tumor volume, and duration of follow-up* Characteristic Mean Median Range SD tumor margin dose (Gy) max dose (Gy) tumor vol (cm 3 ) follow-up after GKRS (mos) * SD = standard deviation J Neurosurg / Volume 120 / June 2014
4 Radiosurgery of parasellar meningiomas TABLE 3: Clinical and radiographic outcomes of GKRS Outcome (no. evaluable patients) Effect of Tumor Margin Dose The median tumor margin dose was 13 Gy (range 5 30 Gy) to a median treatment volume of 6.7 cm 3 (range ; Table 2). A decreasing tumor margin dose (HR = 1.09, 95% CI , p = 0.017) and decreasing maximum dose (HR = 1.03, 95% CI , p = 0.087) were predictive of tumor progression on univariate analysis. Patients receiving a margin dose 13 Gy were 1.6 times less likely to have tumor progression (95% CI , p = 0.50; Fig. 4). J Neurosurg / Volume 120 / June 2014 % Evaluable Patients neurological condition (737) improved worse no change improvement in preexisting CN deficit (737)* 34 II 5.50 III 5.50 IV 1.10 V VI worse or new CN deficit (737) 9.60 II 3.00 III 2.20 IV 0.40 V 4.70 VI 1.10 any new or worsened hypopituitarism (719) 1.80 cortisol 0.30 thyroid hormone 0.70 gonadotropin 0.40 growth hormone 0.10 diabetes insipidus 0.40 panhypopituitarism 0.10 tumor size (758) increase 9.8 decrease 44.1 no change 46.2 further surgery (690) 3.30 further radiation therapy (687) 3.20 overall outcome (732) favorable unfavorable * Some patients demonstrated improvement of more than one CN. Seventy patients had 96 deficits, and some patients had more than one CN deficit. Twelve patients had 15 cases of new or worsening pituitary function, and 1 patient had panhypopituitarism. Actuarial tumor control was 99%, 98%, 95%, 88%, 82%, and 74% at 2, 3, 5, 8, 10, and 12 years, respectively. Favorable outcome = no new or worsening neurological function and tumor control. Fig. 1. Tumor-free progression after GKRS. Censored data are indicated by the circles. Integer values below the x-axis reflect the number of patients at each interval of the Kaplan-Meier analysis. On multivariate analysis, both a history of more than one surgery a history of fractionated radiation therapy were significant predictors of tumor progression (Table 4). These remained significant predictors of tumor progression even after controlling for increasing tumor margin dose (HR = 0.88, 95% CI , p = 0.009). Clinical Response At the last clinical follow-up, overall neurological function worsened in 102 (13.8%) of 737 patients, improved in 229 (31.1%), and remained stable in 406 (55.1%; Table 3). New or worsening CN deficits were observed in 9.6% of patients. Cranial nerves II (3%) and V (4.7%) were the nerves that most often demonstrated new or worsening dysfunction following GKRS. Additional CN deficits following GKRS are detailed in Table 3. Among the patients with CN deficits, 25 (24.5%) had tumor progression, and 77 (75.5%) demonstrated no change or a decrease in tumor volume. In those patients with CN II dysfunction and no evidence of tumor growth, the maximum dose to the optic apparatus was possible in 45% of cases, and in those cases, the maximum dose to the optic apparatus ranged from 0.75 to 8 Gy. One hundred seventy-nine (34%) of 529 patients with prior CN deficits showed improvement in at least one deficit following GKRS. Some patients demonstrated improvement in more than one CN following radiosurgery (Table 3). Among those with improvement, the distribution by CN was as follows: II, 12.5%; III, 12.5%; IV, 2.5%; V, 50%; and VI, 22.5%. 1271
5 J. P. Sheehan et al. Fig. 2. Tumor-free progression in patients with and without a history of surgery prior to GKRS. Censored data are indicated by circles and triangles. Integer values below the x-axis reflect the number of patients at each interval of the Kaplan-Meier analysis. Endocrine Response Endocrine function after GKRS was recorded in 719 patients. After GKRS, new or worsened endocrine deficiencies were demonstrated in 1.8% of patients at the last follow-up (Table 3). Thyroid hormone dysfunction was the most frequent endocrinopathy post-gkrs. Panhypopituitarism was rare and occurred in only one patient who also demonstrated tumor progression on follow-up imaging. Other Serious Complications In the current series, no evidence of radiosurgeryrelated neoplasia, symptomatic carotid artery occlusion, or treatment-related stroke was observed. Overall Outcome An overall favorable outcome was demonstrated in 583 patients (79.6%) who had no tumor progression, no worsening of a preexisting CN deficit, and no new deficit. An unfavorable outcome occurred in 149 (20.4%) of 732 patients. Preradiosurgical patient and tumor characteristics predictive of an unfavorable outcome on univariate analysis are demonstrated in Table 5. There was no difference in overall outcome between patients who underwent resection prior to radiosurgery and those who underwent primary radiosurgery (OR = 1.24, 95% CI , p = Fig. 3. Tumor-free progression in patients with and without prior radiation therapy. Censored data are indicated by the circles and triangles. Integer values below the x-axis reflect the number of patients at each interval of the Kaplan-Meier analysis. RT = radiation therapy ). However, those with more than one surgery were 1.5 times more likely to have an unfavorable outcome (95% CI , p = 0.007). Increasing tumor volume was associated with an unfavorable outcome (1.03, 95% CI , p < 0.008); an unfavorable outcome occurred in 16.9% of patients with a tumor volume < 5 cm 3, 20.2% of patients with a tumor volume between 5 and 15 cm 3, and 24.2% of patients with a tumor volume > 15 cm 3. Analysis of SRS-associated variables demonstrated that a decreasing tumor margin dose (OR = 1.10, 95% CI , p = 0.016) and maximal dose (1.04, 95% CI , p = 0.019) were associated with unfavorable outcomes on univariate analysis. Unfavorable outcomes occurred in 22.8% of patients receiving a peripheral dose < 14 Gy, 16.9% of patients receiving Gy, and 17.7% of patients receiving more than 18 Gy. On multivariate analysis, patients with a history of more than one surgery (OR = 1.37, 95% CI , p = 0.021) and a larger tumor volume (OR = 1.02, 95% CI , p = 0.022) were more likely to have unfavorable outcomes. When adding SRS-associated variables to the multivariate models, a history of more than 1 surgery was the most significant predictor of an unfavorable outcome (OR = 1.4, 95% CI , p = 0.016). We noted a trend toward an unfavorable outcome with increasing tumor volume (OR = 1.03, 95% CI , p = 0.076) and decreasing tumor margin dose (OR = 1.08, 95% CI , p = 0.069) J Neurosurg / Volume 120 / June 2014
6 Radiosurgery of parasellar meningiomas TABLE 4: Preradiosurgical factors predictive of tumor progression* Covariate Univariate Analysis Multivariate Analysis HR (95% CI) p Value HR (95% CI) p Value history of radiation therapy 7.71 ( ) < ( ) <0.001 increasing volume 1.02 ( ) history of > 1 surgery 1.65 ( ) ( ) * Factors predictive of tumor recurrence have p < Discussion Natural History of Sellar and Parasellar Meningiomas The natural history of sellar and parasellar meningiomas is not well defined. In a recent systematic review of 22 studies covering the natural history of meningiomas, cavernous sinus lesions produced new or progressive symptoms 61% of the time over a median follow-up of 4.6 years. 55 Additionally, the authors found specific patterns of tumor growth and size that were more likely to generate symptoms. For example, lesions cm in size and growing more than 10% per year had a 42.3% rate of symptom development. Compare this with lesions smaller than 2 cm with less than 10% annual growth having a 0% rate of symptom development. In contrast, Bindal et al. described the natural history of 40 untreated meningiomas located in the cavernous sinus, petroclival region, or anterior clinoidal region. 3 Fig. 4. Tumor-free progression in patients as a function of radiosurgical dose to the tumor margin. Censored data are indicated by circles. Integer values below the x-axis reflect the number of patients at each interval of the Kaplan-Meier analysis. J Neurosurg / Volume 120 / June 2014 Clinically, 28 patients (70%) presented with a CN deficit and 11 patients (27.5%) were asymptomatic. Over a mean clinical follow-up of 83 months, 11 patients (27.5%) experienced new or worsening CN deficits. During a mean radiographic follow-up of 76 months, 7 patients (17.5%) demonstrated tumor growth. The authors noted that there was a poor correlation between clinical and radiographic changes. In particular, 54.5% of patients with neurological progression did not have any changes on neuroimaging, and 27.2% had simultaneous neurological and radiographic progression. 3 Resection and Radiation Therapy Patients with WHO Grade I meningiomas of the parasellar and sellar region are typically expected to live for a long period and to do so with a reasonably high neurological performance status. Surgical removal of meningiomas can be curative but difficult to achieve in this region. Resection via transcranial or transsphenoidal routes has historically been the primary treatment option for patients with sellar and parasellar meningiomas. However, a neurosurgeon s enthusiasm for achieving complete resection must be tempered by the desire to preserve or improve a patient s neurological function. During resection, damage to venous channels or the cavernous segment of the internal carotid artery and traversing the CNs can have serious long-term ramifications for the patient. Complication rates for gross-total resection of meningiomas in the parasellar region vary widely, and adverse events have been reported to occur in between 0% and 60% of patients. 8,36,39,54 Radiation therapy has also been used in selected patients with recurrent meningiomas or in those with significant medical comorbidities in whom resection was considered excessively risky. Control rates for skull base meningiomas after conventional radiation therapy delivering Gy in fractions vary from 75% to 95% at both 5- and 10-year intervals. 7,11,17,32,38 Neurological deficits associated with skull base meningiomas have been noted to improve or remain stable in 69% 100% of patients who undergo conventional fractionated radiation therapy. 11,31,32,38 Complication rates associated with radiation therapy range from 0% to 24%. 34 Injury to adjacent CNs is one of the most commonly reported complications. The risk of radiation-associated injury to the optic apparatus and other CNs varies between 0% and 3%. 34 Recent advances in the use of both photon and proton radiation techniques, intensity-modulated radiation therapy (IMRT), or image-guided radiation therapy (IGRT) have demonstrated no substantive improvement in tumor con- 1273
7 J. P. Sheehan et al. TABLE 5: Preradiosurgical factors predictive of an unfavorable outcome* Factor Univariate Analysis Multivariate Analysis OR 95% CI p Value OR 95% CI p Value history of > 1 surgery history of prior radiation therapy <0.040 increasing tumor vol < increasing follow-up * Favorable outcome = no new or worsening neurological function and tumor control. Factors predictive of tumor recurrence have p < trol or any reduction in complications in the management of meningiomas. 29,33,34,57,59,60 Stereotactic Radiosurgery With the addition of SRS to the neurosurgical and radiation oncology armamentarium, the pendulum has swung away from both aggressive resection and fractionated radiation therapy for sellar and parasellar meningiomas. Instead, management options have more commonly switched to early radiosurgery for smaller-volume tumors or subtotal resection followed by radiosurgery for larger-volume tumors with symptomatic mass effect. Both strategies place a premium on the preservation of neurological function. In a recent meta-analysis of patients undergoing treatment for cavernous sinus meningioma, SRS together with resection led to improved rates of tumor control compared with surgery alone, and this benefit was afforded regardless of the extent of tumor resection. 54 Moreover, the rate of cranial neuropathy in patients undergoing resection was significantly higher than that in patients undergoing radiosurgery alone. The widespread availability of CT and MRI has led to the detection of parasellar and sellar meningiomas in patients who demonstrate few or no symptoms. Stereotactic radiosurgery has become even more appealing as an upfront treatment in patients unwilling to accept the risks of resection. Selecting SRS as the initial method of management is based on clinical and imaging evidence that the lesion is in fact a meningioma. Magnetic resonance imaging and CT cannot provide confirmation of a histologically benign meningioma. However, in a cohort of 219 patients with image-diagnosed meningiomas, a detailed history, clinical examination, and careful review of the neuroimaging studies yielded a 10-year actuarial misdiagnosis rate of 2.3% ± 1.4%. 14 The actuarial tumor control rate in this same study was noted to be 93.2% ± 2.7% at 10 years postradiosurgery. In the current study, there was no statistical difference in tumor control or neurological outcome in patients with histological confirmation of a WHO Grade I meningioma as compared with that in patients receiving a diagnosis via neuroimaging and clinical features alone. Our study indicated that an appropriate clinical history coupled with modern neuroimaging studies yields an accurate rate of diagnosis for parasellar and sellar meningiomas. Large series and long-term results for radiosurgical treatment of meningiomas are available. In a series of 972 patients with meningiomas in diverse locations and treated with GKRS at the University of Pittsburgh, the reported actuarial tumor control rates were 93% at 5 years and 87% at both 10 and 15 years. 25 Patients in this series received a median tumor margin dose of 13 Gy. These results confirmed an earlier study of 159 patients from the same institution in which tumor volumes decreased in 3%, remained stable in 60%, and eventually increased in 6% of patients. 27 In a review, Minniti et al. compiled 18 studies with 2919 skull base meningiomas treated with GKRS. 34 The 5-year actuarial control rate was 91%. Seven of the studies (1626 skull base meningiomas) reported an averaged 10-year actuarial control rate of 87.6%. In summarizing all recent large series of more than 100 patients, we found that 5- and 10-year local control rates ranged from 86.2% to 98.5% and 73% to 97%, respectively. 9,19,22,24,26,27,37,51,52,56 In the current study, we observed an overall tumor control rate of 90.2% and 5- and 10-year actuarial control rates of 95% and 82%, respectively. The available literature provides less clarity regarding long-term clinical outcomes after radiosurgery for sellar and parasellar meningiomas. Neurological improvement rates have varied between 8% and 66% in published series. 12,13,19,20,22,24 27,37,51,56 Reported postradiosurgical complication rates have varied between 3% and 40%. Most reports have indicated an average of 8% of patients who experience neurological complications (transient complications in 3% and permanent in 5%). 49 In a series of 159 patients with cavernous sinus meningiomas treated using radiosurgery and with a mean follow-up of 35 months (range months), neurological status improved in 29%, remained stable in 62%, and worsened in 9%. 27 Among those with neurological decline, 1.9% had visual deterioration, 3.1% had new trigeminal nerve dysfunction, 1.3% had oculomotor neuropathy, 0.62% had trochlear neuropathy, 1.3% experienced partial complex seizures, and 0.62% had cognitive deterioration. 27 Long-term complications include CN dysfunction and neurological deficits associated with adverse radiation effects, such as edema and necrosis. Among published series of 100 or more patients, rates of significant long-term complications ranged from 0% to 16% in centers utilizing median doses of Gy. 9,12,13,19,20,24 27,37,56 An analysis by a group from the University of California, San Francisco, revealed a pooled cranial neuropathy rate of 59.6% (95% CI %) for patients undergoing resection, as compared with a rate of 25.7% (95% CI %) for those undergoing radiosurgery alone (p < 0.05). 54 In the current study, we observed a 9.6% risk of any new or wors J Neurosurg / Volume 120 / June 2014
8 Radiosurgery of parasellar meningiomas ening cranial neuropathy after GKRS and a 34% chance of improvement in preexisting CN dysfunction following GKRS. Cranial nerves II and V were most likely to demonstrate new or progressive dysfunction following GKRS. Note that we observed radiosurgically induced CN II dysfunction in some patients who had received a maximum dose of 8 Gy or less to the optic apparatus. Thus, despite the 8-Gy dogma, some patients remain susceptible to visual decline even with low doses delivered to the optic apparatus. Overall, our neurological results compare very favorably with those for other treatment options (for example, resection and radiation therapy) as well as for the natural history of a sellar or parasellar meningioma. Overall, a favorable outcome in the current study was defined as tumor regression or stability accompanied by preserved or improved neurological function. A favorable outcome was most commonly seen in patients with a smaller tumor volume and no or only one prior resection. As with many neurosurgical procedures, the failure of one prior procedure often predicts a less successful subsequent intervention. Since radiosurgery is an imageguided surgery, multiple unsuccessful prior resections can make defining the radiosurgical target as well as delineating the critical structures more difficult. In patients with symptomatic larger-volume tumors that produce regional mass effect, we favor initial surgery to reduce the tumor volume followed by early radiosurgery. We did not observe a difference in overall outcomes between patients with upfront radiosurgery and those with 1 prior surgery. Rare Complications After Radiosurgery Delayed endocrinopathy after GKRS was rare in the current study, although thyroid deficiency was the most common. Periodic evaluation of thyroid function seems prudent in patients who demonstrate symptoms of hypothyroidism, and hormonal replacement for endocrinopathy is typically advisable. The actual incidence of delayed endocrine dysfunction in the present series may be underestimated since testing generally occurred at the discretion of the referring physician. The delayed development of radiation-related tumors or stroke was not observed in the current study. Radiosurgery-related tumor development has a reported risk between 0 and 3 cases per 200,000 patients, a risk that does not exceed the incidence of cancer development in the general population. 15,44 Several reports on the development of glioblastomas after radiosurgery have been published. 16,30,45,48,61 Such case reports cannot define the actual risk, but the selection of a treatment recommendation must weigh many factors. Even low doses of radiation (for example, mgy from CT scans) or frequent dental radiography has been linked to an increased risk of brain tumor formation. 18,42 Brada et al. reported that the 5- and 10-year actuarial incidence of stroke after radiation therapy ranges from 4% to 11% of patients. 4 In the current study, we did not observe a single case of treatment-related ischemic cerebrovascular disease. The low risk of either radiation-related neoplasms or stroke provides further evidence of the favorable risk/benefit ratio of SRS as a treatment strategy for parasellar and sellar meningiomas. J Neurosurg / Volume 120 / June 2014 Study Limitations and Biases As the data presented are the result of a retrospective multicenter experience, limitations include patient selection bias and treatment bias at each center. Data were not contributed equally by all centers, and thus biases introduced from larger contributing centers may outweigh those of smaller ones. The parasellar location is sizeable, and the location of meningiomas within this space could include tumors with different natural histories and responses to radiosurgery. Selection bias may have affected the use of upfront radiosurgery, resection, radiation therapy, and salvage radiosurgery at each center. Independent auditing of the data was not performed. Data auditing could be added to future studies and prospective radiosurgical registries. Follow-up patterns varied somewhat from center to center, and this could have contributed to some bias in the study, particularly regarding endocrine deficiencies. In addition, the retrospective nature of the study and the lack of an untreated control group restrict our ability to assess the full benefits of and the complications arising from radiosurgery. Finally, it is not clear to what extent our results are generalizable to other centers. All of the contributing centers used a consistent radiosurgical platform (that is, the Gamma Knife) and dose planning software. Moreover, many of the clinicians at the contributing centers have had a decade or more of experience in radiosurgery, and the centers have a reputation for being high-volume centers with an extensive commitment to outcomes research. The clinicians experience and the radiosurgical techniques at the centers have been refined in a way that may have favorably affected patient selection and outcomes. Conclusions Stereotactic radiosurgery affords a high rate of tumor control for sellar and parasellar meningiomas. After radiosurgery, neurological preservation or improvement was observed in the majority of patients. Favorable outcomes of tumor control and neurological preservation were more likely in patients without multiple prior surgeries, those with smaller tumors, and those in whom a higher tumor margin dose was delivered. Acknowledgments Dr. Kyun-Jae Park and Aditya Iyer, M.Eng., assisted with the project at the University of Pittsburgh. Disclosure The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Drs. Lunsford, Petti, and Kondziolka are consultants for Elekta AB. Dr. Lunsford is also a shareholder in Elekta. Author contributions to the study and manuscript preparation include the following. Conception and design: Sheehan, Kondziolka, Lunsford. Acquisition of data: Sheehan, Kano, Kaufmann, Mathieu, Zeiler, West, Chao, Varma, Chiang, Yu, McBride, Nakaji, Youssef, Honea, Rush, Kondziolka, Lee, Bailey, Kunwar, Petti. Analysis and interpretation of data: Sheehan, Starke. Drafting the article: Sheehan. Critically revising the article: all authors. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Sheehan. 1275
9 J. P. Sheehan et al. References 1. Altman DG: Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC, Bassiouni H, Asgari S, Stolke D: Tuberculum sellae meningiomas: functional outcome in a consecutive series treated microsurgically. Surg Neurol 66:37 45, Bindal R, Goodman JM, Kawasaki A, Purvin V, Kuzma B: The natural history of untreated skull base meningiomas. Surg Neurol 59:87 92, Brada M, Burchell L, Ashley S, Traish D: The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Phys 45: , Cavallo LM, Cappabianca P, Galzio R, Iaconetta G, de Divitiis E, Tschabitscher M: Endoscopic transnasal approach to the cavernous sinus versus transcranial route: anatomic study. Neurosurgery 56 (2 Suppl): , Chi JH, McDermott MW: Tuberculum sellae meningiomas. Neurosurg Focus 14(6):E6, Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL: Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 39: , DeMonte F, Smith HK, al-mefty O: Outcome of aggressive removal of cavernous sinus meningiomas. J Neurosurg 81: , DiBiase SJ, Kwok Y, Yovino S, Arena C, Naqvi S, Temple R, et al: Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas. Int J Radiat Oncol Biol Phys 60: , Dolenc VV: Transcranial epidural approach to pituitary tumors extending beyond the sella. Neurosurgery 41: , Dufour H, Muracciole X, Métellus P, Régis J, Chinot O, Grisoli F: Long-term tumor control and functional outcome in patients with cavernous sinus meningiomas treated by radiotherapy with or without previous surgery: is there an alternative to aggressive tumor removal? Neurosurgery 48: , Eustacchio S, Trummer M, Fuchs I, Schröttner O, Sutter B, Pendl G: Preservation of cranial nerve function following Gamma Knife radiosurgery for benign skull base meningiomas: experience in 121 patients with follow-up of 5 to 9.8 years. Acta Neurochir Suppl 84:71 76, Feigl GC, Samii M, Horstmann GA: Volumetric follow-up of meningiomas: a quantitative method to evaluate treatment outcome of gamma knife radiosurgery. Neurosurgery 61: , Flickinger JC, Kondziolka D, Maitz AH, Lunsford LD: Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int J Radiat Oncol Biol Phys 56: , Ganz JC: Gamma knife radiosurgery and its possible relationship to malignancy: a review. J Neurosurg 97 (5 Suppl): , Ganz JC, Reda WA, Abdelkarim K: Gamma Knife surgery of large meningiomas: early response to treatment. Acta Neurochir (Wien) 151:1 8, Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to J Neurosurg 80: , 1994 (Erratum in J Neurosurg 80:777, 1994) 18. Han YY, Berkowitz O, Talbott E, Kondziolka D, Donovan M, Lunsford LD: Are frequent dental x-ray examinations associated with increased risk of vestibular schwannoma? Clinical article. J Neurosurg 117 Suppl:78 83, Hasegawa T, Kida Y, Yoshimoto M, Koike J, Iizuka H, Ishii D: Long-term outcomes of Gamma Knife surgery for cavernous sinus meningioma. J Neurosurg 107: , Hudgins WR, Barker JL, Schwartz DE, Nichols TD: Gamma Knife treatment of 100 consecutive meningiomas. Stereotact Funct Neurosurg 66 (Suppl 1): , Ichinose T, Goto T, Ishibashi K, Takami T, Ohata K: The role of radical microsurgical resection in multimodal treatment for skull base meningioma. Clinical article. J Neurosurg 113: , 2010 (Erratum in J Neurosurg 113:1123, 2010) 22. Iwai Y, Yamanaka K, Ikeda H: Gamma Knife radiosurgery for skull base meningioma: long-term results of low-dose treatment. Clinical article. J Neurosurg 109: , Jääskeläinen J: Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 26: , Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L: Gamma Knife surgery for benign meningioma. J Neurosurg 107: , Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, et al: Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery 62:53 60, Kreil W, Luggin J, Fuchs I, Weigl V, Eustacchio S, Papaefthymiou G: Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry 76: , Lee JY, Niranjan A, McInerney J, Kondziolka D, Flickinger JC, Lunsford LD: Stereotactic radiosurgery providing longterm tumor control of cavernous sinus meningiomas. J Neurosurg 97:65 72, Linskey ME, Davis SA, Ratanatharathorn V: Relative roles of microsurgery and stereotactic radiosurgery for the treatment of patients with cranial meningiomas: a single-surgeon 4-year integrated experience with both modalities. J Neurosurg 102 Suppl:59 70, Lo SS, Cho KH, Hall WA, Kossow RJ, Hernandez WL, Mc- Collow KK, et al: Single dose versus fractionated stereotactic radiotherapy for meningiomas. Can J Neurol Sci 29: , Loeffler JS, Niemierko A, Chapman PH: Second tumors after radiosurgery: tip of the iceberg or a bump in the road? Neurosurgery 52: , Maire JP, Caudry M, Guérin J, Célérier D, San Galli F, Causse N, et al: Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy, and tolerance in 91 patients. Int J Radiat Oncol Biol Phys 33: , Mendenhall WM, Morris CG, Amdur RJ, Foote KD, Friedman WA: Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer 98: , Metellus P, Regis J, Muracciole X, Fuentes S, Dufour H, Nanni I, et al: Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy. Neurosurgery 57: , Minniti G, Amichetti M, Enrici RM: Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol 4:42, Natarajan SK, Sekhar LN, Schessel D, Morita A: Petroclival meningiomas: multimodality treatment and outcomes at longterm follow-up. Neurosurgery 60: , Newman S: A prospective study of cavernous sinus surgery for meningiomas and resultant common ophthalmic complications (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 105: , Nicolato A, Foroni R, Alessandrini F, Maluta S, Bricolo A, Gerosa M: The role of Gamma Knife radiosurgery in the management of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 53: , Nutting C, Brada M, Brazil L, Sibtain A, Saran F, Westbury C, et al: Radiotherapy in the treatment of benign meningioma of the skull base. J Neurosurg 90: , O Sullivan MG, van Loveren HR, Tew JM Jr: The surgical 1276 J Neurosurg / Volume 120 / June 2014
10 Radiosurgery of parasellar meningiomas resectability of meningiomas of the cavernous sinus. Neurosurgery 40: , Otani N, Muroi C, Yano H, Khan N, Pangalu A, Yonekawa Y: Surgical management of tuberculum sellae meningioma: role of selective extradural anterior clinoidectomy. Br J Neurosurg 20: , Parkinson D: Lateral sellar compartment: history and anatomy. J Craniofac Surg 6:55 68, Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, et al: Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 380: , Roberti F, Sekhar LN, Kalavakonda C, Wright DC: Posterior fossa meningiomas: surgical experience in 161 cases. Surg Neurol 56:8 21, Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A: Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery 60:60 66, Salvati M, Frati A, Russo N, Caroli E, Polli FM, Minniti G, et al: Radiation-induced gliomas: report of 10 cases and review of the literature. Surg Neurol 60:60 67, Sanna M, Bacciu A, Pasanisi E, Taibah A, Piazza P: Posterior petrous face meningiomas: an algorithm for surgical management. Otol Neurotol 28: , Sekhar LN, Swamy NK, Jaiswal V, Rubinstein E, Hirsch WE Jr, Wright DC: Surgical excision of meningiomas involving the clivus: preoperative and intraoperative features as predictors of postoperative functional deterioration. J Neurosurg 81: , Shamisa A, Bance M, Nag S, Tator C, Wong S, Norén G, et al: Glioblastoma multiforme occurring in a patient treated with gamma knife surgery. Case report and review of the literature. J Neurosurg 94: , Sheehan JP, Williams BJ, Yen CP: Stereotactic radiosurgery for WHO grade I meningiomas. J Neurooncol 99: , Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, Lohse CM, et al: Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through Mayo Clin Proc 73: , Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ, et al: Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery 49: , Starke RM, Williams BJ, Hiles C, Nguyen JH, Elsharkawy MY, Sheehan JP: Gamma Knife surgery for skull base meningiomas. Clinical article. J Neurosurg 116: , Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, et al: The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. Clinical article. J Neurosurg 113: , Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT: Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. Clin ical article. J Neurosurg 113: , Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT: Treatment decision making based on the published natural history and growth rate of small meningiomas. A review and meta-analysis. J Neurosurg 113: , Takanashi M, Fukuoka S, Hojyo A, Sasaki T, Nakagawara J, Nakamura H: Gamma knife radiosurgery for skull-base meningiomas. Prog Neurol Surg 22:96 111, Torres RC, Frighetto L, De Salles AA, Goss B, Medin P, Solberg T, et al: Radiosurgery and stereotactic radiotherapy for intracranial meningiomas. Neurosurg Focus 14(5):E5, Voss NF, Vrionis FD, Heilman CB, Robertson JH: Meningiomas of the cerebellopontine angle. Surg Neurol 53: , Weber DC, Lomax AJ, Rutz HP, Stadelmann O, Egger E, Timmermann B, et al: Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol 71: , Weber DC, Schneider R, Goitein G, Koch T, Ares C, Geismar JH, et al: Spot scanning-based proton therapy for intracranial meningioma: long-term results from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys 83: , Zachenhofer I, Wolfsberger S, Aichholzer M, Bertalanffy A, Roessler K, Kitz K, et al: Gamma-knife radiosurgery for cranial base meningiomas: experience of tumor control, clinical course, and morbidity in a follow-up of more than 8 years. Neu rosurgery 58:28 36, 2006 Manuscript submitted January 18, Accepted February 4, Please include this information when citing this paper: published online March 28, 2014; DOI: / JNS Address correspondence to: Jason P. Sheehan, M.D., Ph.D., Department of Neurological Surgery, University of Virginia, Box , Charlottesville, VA jsheehan@virginia.edu. J Neurosurg / Volume 120 / June
Gamma Knife radiosurgery of large skull base meningiomas
clinical article J Neurosurg 122:363 372, 2015 Gamma Knife radiosurgery of large skull base meningiomas Robert M. Starke, MD, MSc, 1 Colin J. Przybylowski, BS, 2 Mukherjee Sugoto, MD, 3 Francis Fezeu,
More informationStereotactic Radiosurgery for Skull Base Meningioma
Neurol Med Chir (Tokyo) 49, 456 461, 2009 Stereotactic Radiosurgery for Skull Base Meningioma Hiroshi IGAKI*, **, KeisukeMARUYAMA***, Tomoyuki KOGA***, Naoya MURAKAMI**, Masao TAGO**,,AtsuroTERAHARA**,
More informationImpact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined Approach
Radiosurgery as part of the neurosurgical armamentarium: Educational Symposium November 24 th 2011 Impact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined
More informationUpdate on IGKRF Activities
Stereotactic radiosurgery research, education and publishing for the purpose of improving public health Fall 2016 In this issue: Update on IGKRF Activities The IGKRF Recently Published Articles Topics
More informationStereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas
Stereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas Treatment Results on the Basis of a 22-Year Experience Bruce E. Pollock, MD 1,2 ; Scott L. Stafford, MD
More informationCerebellopontine angle (CPA) meningiomas are a. Stereotactic radiosurgery for cerebellopontine angle meningiomas. Clinical article
J Neurosurg 120:708 715, 2014 AANS, 2014 Stereotactic radiosurgery for cerebellopontine angle meningiomas Clinical article Seong-Hyun Park, M.D., Ph.D., 1,3,4 Hideyuki Kano, M.D., Ph.D., 1,3 Ajay Niranjan,
More informationEstimating the Risks of Adverse Radiation Effects After Gamma Knife Radiosurgery for Arteriovenous Malformations
Estimating the Risks of Adverse Radiation Effects After Gamma Knife Radiosurgery for Arteriovenous Malformations Hideyuki Kano, MD, PhD; John C. Flickinger, MD; Daniel Tonetti, MD; Alan Hsu, MD; Huai-che
More informationA lthough more than 90% of intracranial meningiomas are
226 PAPER Complications after gamma knife radiosurgery for benign meningiomas J H Chang, J W Chang, J Y Choi, Y G Park, S S Chung... See end of article for authors affiliations... Correspondence to: Professor
More informationLONG-TERM FOLLOW-UP OF ACOUSTIC SCHWANNOMA RADIOSURGERY WITH MARGINAL TUMOR DOSES OF 12 TO 13 Gy
doi:10.1016/j.ijrobp.2007.01.001 Int. J. Radiation Oncology Biol. Phys., Vol. 68, No. 3, pp. 845 851, 2007 Copyright 2007 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/07/$ see front
More informationLong-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure?
J Neurosurg (Suppl) 102:119 123, 2005 Long-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure? TATSUYA KOBAYASHI, M.D., PH.D., YOSHIMASA
More informationGamma knife radiosurgery for Koos grade 4 vestibular schwannomas
Gamma knife radiosurgery for Koos grade 4 vestibular schwannomas David Mathieu MD FRCSC, Christian Iorio-Morin MD PhD, Fahd Al Subaie MD MSc FRCSC Division of neurosurgery, Université de Sherbrooke, Centre
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
More informationPetroclival meningiomas resected via a combined transpetrosal approach: surgical outcomes in 60 cases and a new scoring system for clinical evaluation
clinical article J Neurosurg 122:373 380, 2015 Petroclival meningiomas resected via a combined transpetrosal approach: surgical outcomes in 60 cases and a new scoring system for clinical evaluation Hiroki
More informationResults of acoustic neuroma radiosurgery: an analysis of 5 years experience using current methods
See the Letter to the Editor and the Response in this issue in Neurosurgical Forum, pp 141 142. J Neurosurg 94:1 6, 2001 Results of acoustic neuroma radiosurgery: an analysis of 5 years experience using
More informationEvaluation of linear accelerator-based stereotactic radiosurgery in the management of meningiomas: a single center experience
JBUON 2013; 18(3): 717-722 ISSN: 1107-02, online ISSN: 2241-293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Evaluation of linear accelerator-based stereotactic radiosurgery in the
More informationWe have previously reported good clinical results
J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional
More informationPostoperative LINAC-Based Stereotactic Radiotherapy for Grade I Intracranial Meningioma in Subtype Classification
Postoperative LINAC-Based Stereotactic Radiotherapy for Grade I Intracranial Meningioma in Subtype Classification Peerapong Lueangapapong MD*, Mantana Dhanachai MD**, Ake Hansasuta MD* * Division of Neurosurgery,
More information11/27/2017. Modern Treatment of Meningiomas. Disclosures. Modern is Better? No disclosures relevant to this presentation
Modern Treatment of Meningiomas Michael A. Vogelbaum MD, PhD Professor of Neurosurgery Cleveland Clinic Disclosures No disclosures relevant to this presentation IP and royalties related to drug and device
More informationSurvival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery
ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.
More informationSerial Follow-up MR Imaging after Gamma Knife Radiosurgery for Vestibular Schwannoma
AJNR Am J Neuroradiol 21:1540 1546, September 2000 Serial Follow-up MR Imaging after Gamma Knife Radiosurgery for Vestibular Schwannoma Hiroyuki Nakamura, Hidefumi Jokura, Kou Takahashi, Nagatoshi Boku,
More informationNeurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex
ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):111-115 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.111 Neurological Change after Gamma Knife Radiosurgery for Brain Metastases
More informationAlessandra Gorgulho, MD, MSc
Manejo do Meningioma que compromete o seio cavernoso: quando eu irradio Alessandra Gorgulho, MD, MSc Chefe Clínico-Científica Centro HCor de Neurociências Professora Visitante, Departamento de Neurocirurgia,
More informationKEY WORDS chondrosarcoma; Gamma Knife; stereotactic radiosurgery; skull base tumor; oncology
clinical article J Neurosurg 123:1268 1275, 2015 Skull base chondrosarcoma radiosurgery: report of the North American Gamma Knife Consortium Hideyuki Kano, MD, PhD, 1 Jason Sheehan, MD, PhD, 2 Penny K.
More informationRadiotherapy in the management of optic pathway gliomas
Turkish Journal of Cancer Vol.30/ No.1/2000 Radiotherapy in the management of optic pathway gliomas FARUK ZORLU, FERAH YILDIZ, MURAT GÜRKAYNAK, FADIL AKYOL, İ. LALE ATAHAN Department of Radiation Oncology,
More informationAlthough histologically benign, tumors LONG-TERM RESULTS AFTER RADIOSURGERY FOR BENIGN INTRACRANIAL TUMORS CLINICAL STUDIES
CLINICAL STUDIES LONG-TERM RESULTS AFTER RADIOSURGERY FOR BENIGN INTRACRANIAL TUMORS Douglas Kondziolka, M.D. Narendra Nathoo, M.D. John C. Flickinger, M.D. Ajay Niranjan, M.Ch. Ann H. Maitz, M.S. L. Dade
More informationStereotactic radiosurgery (SRS) is the least invasive
» This article has been updated from its originally published version to correct Table 1 and terminology in the text. See the corresponding erratum notice, DOI: 10.3171/2017.3.JNS151624a. «CLINICAL ARTICLE
More informationEvidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY
GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report
More informationOtolaryngologist s Perspective of Stereotactic Radiosurgery
Otolaryngologist s Perspective of Stereotactic Radiosurgery Douglas E. Mattox, M.D. 25 th Alexandria International Combined ORL Conference April 18-20, 2007 Acoustic Neuroma Benign tumor of the schwann
More informationS tereotactic radiosurgery, whether delivered by a gamma
1536 PAPER Gamma knife stereotactic radiosurgery for unilateral acoustic neuromas J G Rowe, M W R Radatz, L Walton, A Hampshire, S Seaman, A A Kemeny... See end of article for authors affiliations... Correspondence
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:
More informationThe New England Journal of Medicine LONG-TERM OUTCOMES AFTER RADIOSURGERY FOR ACOUSTIC NEUROMAS
LONG-TERM OUTCOMES AFTER RADIOSURGERY FOR ACOUSTIC NEUROMAS DOUGLAS KONDZIOLKA, M.D., L. DADE LUNSFORD, M.D., MARK R. MCLAUGHLIN, M.D., AND JOHN C. FLICKINGER, M.D. ABSTRACT Background Stereotactic radiosurgery
More informationFractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: a retrospective cohort study.
Thomas Jefferson University Jefferson Digital Commons Department of Radiation Oncology Faculty Papers Department of Radiation Oncology 1-1-2012 Fractionated stereotactic radiation therapy improves cranial
More informationExtracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 2, SPRING 2006 Extracranial doses in stereotactic and conventional radiotherapy for pituitary adenomas Thomas Samuel Ram, a Paul B. Ravindran,
More informationThe primary management of the majority of symptomatic
J Neurosurg 116:1304 1310, 2012 Cranial nerve dysfunction following Gamma Knife surgery for pituitary adenomas: long-term incidence and risk factors Clinical article Christopher P. Cifarelli, M.D., Ph.D.,
More informationIMAGE-GUIDED RADIOSURGERY USING THE GAMMA KNIFE
IMAGE-GUIDED RADIOSURGERY USING THE GAMMA KNIFE L. D. LUNSFORD INTRODUCTION Image guided brain surgery became a reality in the mid-1970s after the introduction of the first methods to obtain axial imaging
More informationRadioterapia degli adenomi ipofisari
Radioterapia degli adenomi ipofisari G Minniti Radiation Oncology, Sant Andrea Hospital, University of Rome Sapienza, and IRCCS Neuromed, Pozzilli (IS) Roma 6-9 Novembre 14 ! Outline " Radiation techniques
More informationMichael K. Morgan, MD, 1 Markus K. Hermann Wiedmann, MD, 1 Marcus A. Stoodley, PhD, 1 and Gillian Z. Heller, PhD 2
CLINICAL ARTICLE J Neurosurg 127:1105 1116, 2017 Microsurgery for Spetzler-Ponce Class A and B arteriovenous malformations utilizing an outcome score adopted from Gamma Knife radiosurgery: a prospective
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015
More informationParagangliomas of the head and neck, also known
J Neurosurg 121:1158 1165, 2014 AANS, 2014 Jugulotympanic paragangliomas treated with Gamma Knife radiosurgery: a single-center review of 58 cases Clinical article Maria Luisa Gandía-González, M.D., 1
More informationParaganglioma of the Skull Base. Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI
Paraganglioma of the Skull Base Ross Zeitlin, MD Medical College of Wisconsin Milwaukee, WI Case Presentation 63-year-old female presents with right-sided progressive conductive hearing loss for several
More informationAfter an evolution of more than 3 decades, stereotactic
Neuro-Oncology Advance Access published May 3, 2012 Neuro-Oncology doi:10.1093/neuonc/nos085 NEURO-ONCOLOGY Therapeutic profile of single-fraction radiosurgery of vestibular schwannoma: unrelated malignancy
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationInjury to the facial nerve is a common complication. Efficacy of facial nerve sparing approach in patients with vestibular schwannomas
See the corresponding editorial in this issue, pp 915 916. J Neurosurg 115:917 923, 2011 Efficacy of facial nerve sparing approach in patients with vestibular schwannomas Clinical article Raqeeb Haque,
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationThe clinical significance of persistent trigeminal nerve contrast enhancement in patients who undergo repeat radiosurgery
CLINICAL ARTICLE J Neurosurg 127:219 225, 2017 The clinical significance of persistent trigeminal nerve contrast enhancement in patients who undergo repeat radiosurgery Seyed H. Mousavi, MD, 1 Berkcan
More informationMeningiomas are the most common primary intracranial. Grade 2 meningioma and radiosurgery
clinical article J Neurosurg 122:1157 1162, 2015 Grade 2 meningioma and radiosurgery Rabih Aboukais, MD, 1 Fahed Zairi, MD, 1 Jean-Paul Lejeune, MD, PhD, 1 Emile Le Rhun, MD, 1 Maximilien Vermandel, PhD,
More informationMeningiomas are the most common type of primary. Atypical meningiomas: is postoperative radiotherapy indicated?
Neurosurg Focus 35 (6):E15, 2013 AANS, 2013 Atypical meningiomas: is postoperative radiotherapy indicated? Kangmin D. Lee, M.D., 1,5 John J. DePowell, M.D., 1 Ellen L. Air, M.D., Ph.D., 1,3,4 Alok K. Dwivedi,
More informationSponsored by: Congress of Neurological Surgeons (CNS) and the Section on Tumors
1 2 3 4 5 6 7 8 CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON THE ROLE OF RADIOSURGERY AND RADIATION THERAPY IN THE MANAGEMENT OF PATIENTS WITH VESTIBULAR SCHWANNOMAS
More informationProcess / Evidence Class. Clinical Assessment / III
Table 2: Endocrine Author Cozzi et al (2009) 1 Study Design: Prospectively followed case series. Fourteen patients had pre-op hypocortisolism. Patient Population: Seventy-two adult patients who underwent
More informationUpdate on Pediatric Brain Tumors
Update on Pediatric Brain Tumors David I. Sandberg, M.D. Director of Pediatric Neurosurgery & Associate Professor Dr. Marnie Rose Professorship in Pediatric Neurosurgery Pre-talk Questions for Audience
More informationCyberknife Radiotherapy for Vestibular Schwannoma
Cyberknife Radiotherapy for Vestibular Schwannoma GordonT. Sakamoto, MD a, *, Nikolas Blevins, MD b, Iris C. Gibbs, MD c KEYWORDS Stereotactic radiosurgery Vestibular schwannomas Cyberknife Fractionation
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationNON MALIGNANT BRAIN TUMOURS Facilitator. Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol
NON MALIGNANT BRAIN TUMOURS Facilitator Ros Taylor Advanced Neurosurgical Nurse Practitioner Southmead Hospital Bristol Neurosurgery What will be covered? Meningioma Vestibular schwannoma (acoustic neuroma)
More informationFRACTIONATED STEREOTACTIC RADIOTHERAPY FOR ACOUSTIC NEUROMAS
PII S0360-3016(02)02763-3 Int. J. Radiation Oncology Biol. Phys., Vol. 54, No. 2, pp. 500 504, 2002 Copyright 2002 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/02/$ see front
More informationTABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
More informationStereotactic Radiosurgery for Glossopharyngeal Neuralgia: An International Multicenter Study
Stereotactic Radiosurgery for Glossopharyngeal Neuralgia: An International Multicenter Study University of Pittsburgh Hideyuki Kano, MD, PhD L. Dade Lunsford, MD Hospital Na Homolce, Prague Dusan Urgosik,
More informationANALYSIS OF TREATMENT OUTCOMES WITH LINAC BASED STEREOTACTIC RADIOSURGERY IN INTRACRANIAL ARTERIOVENOUS MALFORMATIONS
ANALYSIS OF TREATMENT OUTCOMES WITH LINAC BASED STEREOTACTIC RADIOSURGERY IN INTRACRANIAL ARTERIOVENOUS MALFORMATIONS Dr. Maitri P Gandhi 1, Dr. Chandni P Shah 2 1 Junior resident, Gujarat Cancer & Research
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationForward treatment planning techniques to reduce the normalization effect in Gamma Knife radiosurgery
Received: 7 November 2016 Revised: 9 August 2017 Accepted: 21 August 2017 DOI: 10.1002/acm2.12193 RADIATION ONCOLOGY PHYSICS Forward treatment planning techniques to reduce the normalization effect in
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationGamma. Knife PERFEXION. care. World-class. The Gamma Knife Program at Washington Hospital
The Gamma Knife Program at Washington Hospital PERFEXION Fast, precise, minimally invasive treatment for neurological conditions. Locally based care by internationally Gamma recognized experts. World-class
More informationSUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT
SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1
More informationAc o u s t i c neuromas, also known as vestibular. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma
J Neurosurg 111:863 873, 2009 Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR HAEMANGIOBLASTOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR HAEMANGIOBLASTOMA QUESTIONS TO BE ADDRESSED: 1. What is the evidence for the clinical effectiveness
More informationImage-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes
Neuro-Oncology Neuro-Oncology 17(6), 889 894, 2015 doi:10.1093/neuonc/nou347 Advance Access date 27 December 2014 Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationGamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop
Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife
More informationRecently, GKS has been regarded as a major therapeutic. Nervus intermedius dysfunction following Gamma Knife surgery for vestibular schwannoma
J Neurosurg 118:566 570, 2013 AANS, 2013 Nervus intermedius dysfunction following Gamma Knife surgery for vestibular schwannoma Clinical article Seong-Hyun Park, M.D., 1 Kyu-Yup Lee, M.D., 2 and Sung-Kyoo
More informationHypofractionated radiosurgery for meningiomas a safer alternative for large tumors?
Original Article Hypofractionated radiosurgery for meningiomas a safer alternative for large tumors? Damon E. Smith 1, Sanjay Ghosh 2, Michael O Leary 2, Colin Chu 1, David Brody 2 1 Genesis Healthcare
More informationOverview of radiosurgery for benign brain tumors
Overview of radiosurgery for benign brain tumors Anuj V. Peddada, M.D. Department of Radiation Oncology Penrose Cancer Center Colorado Springs, CO Objectives Provide overview of benign brain tumors meningiomas
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationAAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve)
AAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve) Michael T. Milano, MD PhD Department of Radiation Oncology University of Rochester, Rochester, NY 07/16/15 AAPM WGSBRT Optic Apparatus NTCP Issam El
More informationGamma Knife surgery for trigeminal schwannoma
J Neurosurg 106:839 845, 2007 Gamma Knife surgery for trigeminal schwannoma JASON SHEEHAN, M.D., PH.D., CHUN PO YEN, M.D., YASSER ARKHA, M.D., DAVID SCHLESINGER, PH.D., AND LADISLAU STEINER, M.D., PH.D.
More informationCraniopharyngiomas (from Greek: κρανίον, skull
J Neurosurg 119:1194 1207, 2013 AANS, 2013 Endoscopic endonasal surgery for craniopharyngiomas: surgical outcome in 64 patients Clinical article Maria Koutourousiou, M.D., 1 Paul A. Gardner, M.D., 1 Juan
More informationStereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13
Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall
More informationRESEARCH HUMAN CLINICAL STUDIES
TOPIC RESEARCH HUMAN CLINICAL STUDIES RESEARCH HUMAN CLINICAL STUDIES Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis Jared R. Robbins, MD* Samuel Ryu, MD* Steven
More informationFOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR PILOCYTIC ASTROCYTOMA
1 EVIDENCE SUMMARY REPORT FOR PUBLIC CONSULTATION ONLY STEREOTACTIC RADIOSURGERY/ STEROTACTIC RADIOTHERAPY FOR PILOCYTIC ASTROCYTOMA QUESTIONS TO BE ADDRESSED: SUMMARY 1. What is the evidence for the clinical
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationTreatment Strategy of Intracranial Hemangiopericytoma
ORIGINAL ARTICLE Brain Tumor Res Treat 2015;3(2):68-74 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2015.3.2.68 Treatment Strategy of Intracranial Hemangiopericytoma Young-Joo Kim
More informationTABLES. Imaging Modalities Evidence Tables Table 1 Computed Tomography (CT) Imaging. Conclusions. Author (Year) Classification Process/Evid ence Class
TABLES Imaging Modalities Evidence Tables Table 1 Computed Tomography (CT) Imaging Author Clark (1986) 9 Reformatted sagittal images in the differential diagnosis meningiomas and adenomas with suprasellar
More informationLong term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas
Pituitary (2010) 13:223 229 DOI 10.1007/s11102-010-0221-z Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas Edward F. Chang Michael E. Sughrue
More informationAcoustic Neuroma. Presenting Signs and Symptoms of an Acoustic Neuroma:
Acoustic Neuroma An acoustic neuroma is a benign tumor which arises from the nerves behind the inner ear and which may affect hearing and balance. The incidence of symptomatic acoustic neuroma is estimated
More informationRadiotherapy for intracranial meningiomas SAMO Interdisciplinary Workshop on Brain Tumors and Metastases November 2016
WIR SCHAFFEN WISSEN HEUTE FÜR MORGEN PD Dr Alessia Pica, Pr Damien Charles Weber: Paul Scherrer Institut Radiotherapy for intracranial meningiomas SAMO Interdisciplinary Workshop on Brain Tumors and Metastases
More informationSkullbase Lesions. Skullbase Surgery Open vs endoscopic. Choice Of Surgical Approaches 12/28/2015. Skullbase Surgery: Evolution
Skullbase Lesions Skullbase Surgery Open vs endoscopic Prof Asim Mahmood,FRCS,FACS,FICS,FAANS, Professor of Neurosurgery Henry Ford Hospital Detroit, MI, USA Anterior Cranial Fossa Subfrontal meningioma
More informationDespite recent progress in microsurgical techniques, endovascular
Application of Single-Stage Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations >10 cm 3 Shunya Hanakita, MD; Tomoyuki Koga, MD, PhD; Masahiro Shin, MD, PhD; Hiroshi Igaki, MD, PhD; Nobuhito
More informationStereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2
Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis Type 2 Brian R. Subach, M.D., Douglas Kondziolka, M.D., M. Sc., F.R.C.S.(C), L. Dade Lunsford, M.D., F.A.C.S.,
More informationSurgical therapeutic strategy for giant pituitary adenomas.
Biomedical Research 2017; 28 (19): 8284-8288 ISSN 0970-938X www.biomedres.info Surgical therapeutic strategy for giant pituitary adenomas. Han-Shun Deng, Zhi-Quan Ding, Sheng-fan Zhang, Zhi-Qiang Fa, Qing-Hua
More informationPreliminary Experience with 3-Tesla MRI and Cushing s Disease
TECHNICAL NOTE Preliminary Experience with 3-Tesla MRI and Cushing s Disease LouisJ.Kim,M.D., 1 Gregory P. Lekovic, M.D., Ph.D., J.D., 1 William L.White, M.D., 1 and John Karis, M.D. 2 ABSTRACT Because
More informationStereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases
ONCOLOGY REPORTS 29: 407-412, 2013 Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases SHELLY LWU 1, PABLO GOETZ 1, ERIC MONSALVES 1, MANDANA ARYAEE 1, JULIUS
More informationLeksell Gamma Knife Icon. Treatment information
Leksell Gamma Knife Icon Treatment information You may be feeling frightened or overwhelmed by your recent diagnosis. It can be confusing trying to process a diagnosis, understand a new and challenging
More information10/23/2010. Excludes Single Surgeon Pituitary (N=~140) Skull Base Volume 12 Month UC SF. Patients. Anterior/Midline. Pituitary CSF Leak.
Advances in Pituitary Surgery Ivan El-Sayed MD, FACS Director- Otolaryngology Minimally Invasive Skull Base Surgery Program Otolaryngology-Head and Neck Surgery University of California-San Francisco Minimally
More informationFractionated Proton Beam Therapy for Acoustic Neuromas: Tumor Control and Hearing Preservation
Fractionated Proton Beam Therapy for Acoustic Neuromas: Tumor Control and Hearing Preservation Carolyn J. Barnes, MD 1 ; David A. Bush, MD 1 ; Roger I. Grove, MPH 1 ; Lilia N. Loredo, MD 1 ; Jerry D. Slater,
More informationGamma Knife radiosurgery with CT image-based dose calculation
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 16, NUMBER 6, 2015 Gamma Knife radiosurgery with CT image-based dose calculation Andy (Yuanguang) Xu, 1a Jagdish Bhatnagar, 1 Greg Bednarz, 1 Ajay Niranjan,
More informationSTEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS
STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS Yousefi Kashi A. SH, Mofid B. 1 Department of Radiation Oncology,Shohada Tajrish Hospital,Shahid Beheshti University
More informationInter- and intrafractional dose uncertainty in hypofractionated Gamma Knife radiosurgery
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 17, NUMBER 2, 2016 Inter- and intrafractional dose uncertainty in hypofractionated Gamma Knife radiosurgery Taeho Kim, 1,3 Jason Sheehan, 2,1 and David
More informationEndoscopic Endonasal Surgery for Subdiaphragmatic Type Craniopharyngiomas
Original Article doi: 10.2176/nmc.oa.2018-0028 Neurol Med Chir (Tokyo) 58, 260 265, 2018 Endoscopic Endonasal Surgery for Subdiaphragmatic Type Craniopharyngiomas Hiroshi NISHIOKA, 1,2 Yuichi NAGATA, 1
More informationGamma Knife Radiosurgery
Gamma Knife Radiosurgery A Team Approach to Treating Patients George Bovis, MD Patrick Sweeney, MD Jagan Venkatesan, MS Matt White, MS Illinois Gamma Knife Center Elk Grove Village, IL Disclosures Shareholders
More information